Literature DB >> 18503193

Essramycin: a first triazolopyrimidine antibiotic isolated from nature.

Mervat M A El-Gendy1, Mohamed Shaaban, Khaled A Shaaban, Ahmed M El-Bondkly, Hartmut Laatsch.   

Abstract

In the course of our screening program for new bio-active compounds, a novel triazolopyrimidine antibiotic, essramycin (1), was obtained from the culture broth of the marine Streptomyces sp., isolate Merv8102. Structure 1 was established by intensive NMR studies and by mass spectra. The compound is antibacterially active with MIC of 2 to 8 microg/ml against Gram-positive and Gram-negative bacteria, while it showed no antifungal activity. The fermentation and isolation, as well as the structure elucidation and biological activity of 1 are described.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18503193     DOI: 10.1038/ja.2008.124

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  18 in total

1.  Production and genetic improvement of a novel antimycotic agent, saadamycin, against dermatophytes and other clinical fungi from endophytic Streptomyces sp. Hedaya48.

Authors:  Mervat M A El-Gendy; Ahmed M A El-Bondkly
Journal:  J Ind Microbiol Biotechnol       Date:  2010-05-12       Impact factor: 3.346

2.  A novel protocol for catalyst-free synthesis of fused six-member rings to triazole and pyrazole.

Authors:  Sedigheh Akrami; Bahador Karami; Mahnaz Farahi
Journal:  Mol Divers       Date:  2019-04-01       Impact factor: 2.943

3.  Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.

Authors:  Marzena Fandzloch; Liliana Dobrzańska; Tomasz Jędrzejewski; Julia Jezierska; Joanna Wiśniewska; Iwona Łakomska
Journal:  J Biol Inorg Chem       Date:  2019-11-18       Impact factor: 3.358

4.  Unconventional Antibacterials and Adjuvants.

Authors:  Mayland Chang; Kiran V Mahasenan; Juan A Hermoso; Shahriar Mobashery
Journal:  Acc Chem Res       Date:  2021-01-29       Impact factor: 22.384

5.  The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.

Authors:  Edison S Zuniga; Aaron Korkegian; Steven Mullen; Erik J Hembre; Paul L Ornstein; Guillermo Cortez; Kallolmay Biswas; Naresh Kumar; Jeffrey Cramer; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Tanya Parish
Journal:  Bioorg Med Chem       Date:  2017-05-19       Impact factor: 3.641

6.  Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids.

Authors:  Shefali Chowdhary; Joel Mosnier; Isabelle Fonta; Bruno Pradines; Nosipho Cele; Pule Seboletswe; Parvesh Singh; Vipan Kumar
Journal:  ACS Med Chem Lett       Date:  2022-06-21       Impact factor: 4.632

7.  Small-molecule inhibitors of ferrochelatase are antiangiogenic agents.

Authors:  Kamakshi Sishtla; Nathan Lambert-Cheatham; Bit Lee; Duk Hee Han; Jaehui Park; Sheik Pran Babu Sardar Pasha; Sanha Lee; Sangil Kwon; Anbukkarasi Muniyandi; Bomina Park; Noa Odell; Sydney Waller; Il Yeong Park; Soo Jae Lee; Seung-Yong Seo; Timothy W Corson
Journal:  Cell Chem Biol       Date:  2022-01-31       Impact factor: 9.039

Review 8.  1,2,4-Triazolo[1,5-a]pyrimidines in drug design.

Authors:  Killian Oukoloff; Bobby Lucero; Karol R Francisco; Kurt R Brunden; Carlo Ballatore
Journal:  Eur J Med Chem       Date:  2019-01-14       Impact factor: 6.514

Review 9.  Antimicrobial compounds from marine actinomycetes.

Authors:  Cong Wang; Yuanyu Lu; Shugeng Cao
Journal:  Arch Pharm Res       Date:  2020-07-20       Impact factor: 4.946

10.  The Natural Product Essramycin and Three of Its Isomers Are Devoid of Antibacterial Activity.

Authors:  Huan Wang; Dusan Hesek; Mijoon Lee; Elena Lastochkin; Allen G Oliver; Mayland Chang; Shahriar Mobashery
Journal:  J Nat Prod       Date:  2016-04-06       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.